Summary Keywords GLP-1, Alzheimers disease, Parkinsons disease, neuroinflammation, amyloid beta, mitochondrial dysfunction, brain glucose hypometabolism, insulin resistance Citation Reich N and Hlscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimers and Parkinsons disease: An in-depth review
Record the time of injection, what you eat, any side effects experienced, and their severity
Youve probably heard buzz about some of these treatments for weight loss too, though theyre primarily for diabetes
While this reduction would present a volume headwind for packaged food and beverage companies and restaurants, companies may also have opportunities to evolve product offerings to adapt to the changing diets of GLP-1 patients, both while they are on the drug and following treatment
Patients ask about it for chronic strain patterns, post-surgical healing, and sports recovery